GGrantIndex
Sort

82,697 grants matching vaccine development

Defending Against Systemic Mycoses

$761,801
George S. Deepe · University Of Cincinnati · P01 · FY2008 · AI

Immune Reconstitution

$761,783
Ronald E. Gress · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

Multivalent Toxoid Vaccine for Prevention of S. aureus Invasive Diseases

$761,776
M. Javad Aman · Integrated Biotherapeutics, Inc. · R01 · FY2019 · AI

Research Project 1: Vaccine for Rapid Response to Filovirus Outbreak

$761,773
Stefan L Hamm · University Of Texas Med Br Galveston · U19 · FY2023 · AI

PrEP and protective immune responses against HIV-1

$761,717
Jared Baeten · University Of Washington · R01 · FY2012 · AI

Bifidobacterium infantis supplementation in early life to improve immunity in infants exposed to HIV: a randomized, placebo-controlled, double-blind trial

$761,676
Heather Beryl Jaspan · Seattle Children'S Hospital · R01 · FY2025 · HD

Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention

$761,618
David Andrew Largaespada · University Of Minnesota · UG3 · FY2020 · CA

Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention

$761,618
David Andrew Largaespada · University Of Minnesota · UG3 · FY2019 · CA

MECHANISMS REGULATING AIRWAY EOSINOPHILIC INFLAMMATION

$761,606
University Of Texas Medical Br Galveston · P01 · FY2000 · AI

Multivalent nanocluster universal influenza vaccine given by microneedle patch

$761,509
Baozhong Wang · Georgia State University · R01 · FY2021 · AI

Project 1: COVID-19 prevalence, transmission, and protection in extended first responder cohorts

$761,461
Eugene M. Oltz · Ohio State University · U54 · FY2020 · CA

Design and characterization of biomimetic nanobiomaterials to elicit CD1-restricted T cell responses during sub-unit vaccination

$761,409
Evan Alexander Scott · Northwestern University · R01 · FY2022 · AI

Design and characterization of biomimetic nanobiomaterials to elicit CD1-restricted T cell responses during sub-unit vaccination

$761,409
Evan Alexander Scott · Northwestern University · R01 · FY2021 · AI

Improving Influenza Vaccination Delivery Across a Health System by the Electronic Health Records Patient Portal

$761,361
Peter G Szilagyi · University Of California Los Angeles · R01 · FY2020 · AI

Supramolecular pediatric HIV vaccine design

$761,359
Joel H Collier · Duke University · R01 · FY2022 · AI

Administrative Core

$761,330
James W. Curran · Emory University · P30 · FY2014 · AI

Intestinal Disease-enterocyte toxin interaction

$761,309
Wayne Lencer · Boston Children'S Hospital · R37 · FY2011 · DK

The NEPRC SPF Rhesus Macaque Breeding Colony

$761,303
R. Paul Johnson · Harvard Medical School · U42 · FY2013 · OD

Effects of a Novel, Scalable, and Sustainable Patient Portal Intervention on Diabetes-Related Outcomes: A Pragmatic Randomized Controlled Trial

$761,289
William Martinez · Vanderbilt University Medical Center · R01 · FY2022 · DK

Urban Water Systems, Enteric Pathogen Distribution & Gut Microbiome Development in Children: A Natural Experiment in Mozambique

$761,233
Karen Levy · Emory University · R01 · FY2019 · AI

Characterizing the therapeutic efficacy of CD8 T cell responses induced by the IL-15 superagonist ALT-803

$761,196
Shelby L Oconnor · University Of Wisconsin-Madison · R01 · FY2019 · AI

Integrative Omics of HepB Vaccine Response in Co-Infection with Parasites

$761,155
Elias K Haddad · Drexel University · U19 · FY2021 · AI

Effect of host immunity stimulated by viral IL-10-deleted RhCMV vaccines on SIV rebound

$761,122
Dennis J Hartigan-O'Connor · University Of California At Davis · P01 · FY2017 · AI

Developing a novel agonist of CD137 for cancer immunoprevention

$761,094
Haval Shirwan · University Of Missouri-Columbia · UG3 · FY2025 · CA

Developing a novel agonist of CD137 for cancer immunoprevention

$761,094
Haval Shirwan · University Of Missouri-Columbia · UG3 · FY2024 · CA